Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
OSONG, Korea - As big pharma continues snatching up biotechs in its quest to fill drying pipelines, very few biotechs will be left standing in 2013, Merck exec Greg Wiederrecht told Bio Korea attendees Oct. 8.
You may also be interested in...
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1
Roche Sets Groundwork For Rapid Expansion In China Through R&D Partnerships
BEIJING - Roche is laying the groundwork for a major new phase in expansion across China through partnerships with promising pharmaceutical research outfits and biotechnology start-ups, according to senior Roche executives